The European Medicines Agency (EMA) on Friday advised against using the AstraZeneca vaccine in people with a history of rare bleeding as a way to prevent an adverse reaction to the drug.
This is the second preventive recommendation by the EMA regarding the vaccine. Last month, the regulator recommended against giving the second dose to people with blood clotting problems.
According to the news provided by “Reuters” agency, the recommendation comes after an investigation that analyzes cases of carditis after vaccination with all vaccines.
The EMA Safety Committee noted in its evaluation that capillary leak syndrome, also known as Clarkson’s disease, should be added to the AstraZeneca package as a new side effect. It is a condition in which blood leaks from the smallest vessels into the muscles and cavities of the body, and is characterized by bloating and low blood pressure.
Reuters reported that the cases began being analyzed in April by the European Medicines Agency, which is also investigating cases of myocarditis and pericarditis following vaccinations from AstraZeneca, Pfizer, Modern and Johnson & Johnson.
Andrea Hargraves is a contributor to Brytfmonline.com, covering a broad range of topics including news, politics, business, technology, sports, entertainment, and lifestyle. She is committed to delivering clear, accurate, and reader-focused reporting that helps audiences stay informed about current events and emerging developments. Andrea’s work emphasizes useful information, balanced coverage, and stories that matter to everyday readers, making complex topics accessible and relevant to a wide audience.